No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SNDX Syndax Pharmaceuticals
- 22.050
- +0.190+0.87%
Close May 3 16:00 ET
- 22.050
- 0.0000.00%
Post 17:29 ET
1.87BMarket Cap-7399P/E (TTM)
22.660High21.900Low704.69KVolume22.390Open21.860Pre Close15.62MTurnover0.83%Turnover RatioLossP/E (Static)84.98MShares25.34052wk High3.38P/B1.87BFloat Cap11.21552wk Low--Dividend TTM84.64MShs Float29.860Historical High--Div YieldTTM3.48%Amplitude3.390Historical Low22.170Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects
Express News | Live On CNBC, StemPoint Capital CIO Michelle Ross Mentioned Syndax Pharmaceuticals, Shares Spiked Higher
Comments
Update
$Syndax Pharmaceuticals(SNDX.US$ Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
Syndax Pharmaceuticals' excess liquidity indicates a cautious approach to debt, but its lack of significant operating revenue and EBIT loss over the last year are worrying. The company's balance sheet appears liquid, but the absence of regular free cash flow generation is concerning.
Update
$Syndax Pharmaceuticals(SNDX.US$ Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
Watching!
$Syndax Pharmaceuticals(SNDX.US$ See a lot of potential here? with price action after trial PR, its like everyone read ( trial stopped early ) but didn’t read any further? it was stopped for efficacy, it showed improvement and are moving on to next phase!
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg